340B Drug Pricing Program Public Comments
BACK TO 340B MAIN POLICY PAGERE: Information Collection Request—340B Rebate Model Pilot Program Application, Implementation and Evaluation (OMB No. 0906-NEW) (July 8, 2026)
RE: Proposed 340B Rebate Model Pilot Program [HHS Docket No. HRSA-2026-03042] (April 19, 2026)
RE: Testimony in opposition to Connecticut Senate Bill 494, Sections 21 & 22 (April 15, 2026)
RE: Testimony in opposition to New York Senate Bill 9007-B, Part W (April 8, 2026)
RE: 340B Rebate Model Pilot [HHS Docket No. HRSA–2025–14619] (September 8, 2025)
RE: CMS Proposed Exclusion of 340B Drug Units from Medicare Inflation Rebate Calculations (September 5, 2025)
RE: Written testimony to the Office of Management & Budget in support of the manufacturer drug rebate model for the 340B Drug Pricing Program (June 25, 2025)
RE: Testimony in opposition to California Assembly Bill 1460 (June 18, 2025)
RE: Testimony in opposition to Texas House Bill 3265 (April 23, 2025)
RE: Testimony in support of Colorado Senate Bill 124 (March 11, 2025)
RE: Testimony in opposition to Connecticut House Bill 6870 (“AN ACT CONCERNING PATIENTS’ PRESCRIPTION DRUG COSTS”) (March 10, 2025)
RE: Testimony in opposition to Michigan Senate Bill 94 (February 25, 2025)
RE: Testimony in opposition to Tennessee Senate Bill 1414 (February 25, 2025)
RE: Testimony in opposition to Tennessee House Bill 1242 (February 25, 2025)
RE: Testimony in opposition to Georgia House Bill 139 (February 11, 2025)
RE: Testimony in opposition to Kentucky Senate Bill 14 (February 11, 2025)
RE: Testimony in opposition to New York Senate Bill 1913 (February 11, 2025)
RE: Testimony in opposition to Connecticut Senate Bill 8 (“AN ACT CONCERNING DRUG AFFORDABILITY”) (March 18, 2024)
RE: U.S. Senate Bipartisan 340B Working Group Request for Information – 340B Drug Pricing Program (July 24, 2023)
RE: Louisiana House Bill 548 - 340B Drug Pricing Program (June 7, 2023)
RE: HIV Community Concerns Over S.4395 (August 15, 2022)
BACK TO 340B MAIN POLICY PAGE